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Guest Editorial
Chronic obstructive pulmonary disease (COPD) is a major
cause of morbidity and mortality worldwide. In spite of this,
it remains a relatively neglected disease, compared, for
example, to asthma, both in terms of public awareness and
in public health planning. Nowhere is this more true than
in developing countries, where the paucity of information
on epidemiology, burden of disease and management is an
impediment to developing adequate strategies for improving
healthcare and reducing the burden of disease attributable
to COPD. In this context, the ﬁndings of the BREATHE study,
a large epidemiological study conducted in ten countries in
the Middle East and North Africa and in Pakistan, provides
the ﬁrst international collaborative attempt to document
the prevalence and burden of COPD in this region of the
world. Its ﬁndings are derived from interviews of over 60,000
respondents in the general population. The study provides
a unique ﬁrst of its kind look at the impact of COPD and
cigarette smoking in this part of the world.
A number of important ﬁndings emerge from the BREATHE
Study which may promote awareness of COPD and thus may
potentially have a signiﬁcant impact on the management of
COPD in the region in coming years. Although the prevalence
of COPD in all participating countries combined was around
four percent, this prevalence, even if it is an underestimate,
is signiﬁcant enough to emphasize the impact of the disease,
since it is similar to that of asthma or chronic heart failure,
ﬁve times greater than the prevalence of bipolar disorder,
and ten times higher than that of epilepsy. As mentioned,
this prevalence rate may be underestimated, since other
risk factors that are frequent in this part of the world, such
as waterpipe smoking or exposure to burning biomass fuel,
were not considered in the determination of prevalence.
This notion is supported by the fact that that the prevalence
of chronic bronchitis, including in non-cigarette smokers, is
even higher. Whereas smoking rates in Europe and North
America have plateaued over recent years, they are still
rising sharply in the Middle East and North Africa, notably in
women. This is partly due to the acceptance of smoking as
a social activity in some cultures and the lack of legislation
regulating smoking in public places. This trend implies that
the prevalence of COPD is likely to rise as more and more
young smokers enter the age groups at higher risk for
symptomatic COPD.
Another important ﬁnding of the BREATHE study was
the documentation of largely unsatisfactory standards of
care in the different countries where it was conducted.
Indeed, fewer than one third of COPD cases were diagnosed,
fewer than one third evaluated for lung function, and fewer
than one third received appropriate treatment for COPD.
In addition, less than 10% of treatment was compliant
with the 2011 GOLD guidelines. A consequence of this
was the extent of healthcare resources mobilised for
taking care of inadequately managed respiratory symptoms.
Indeed, a total of 180 consultations, 30 hospitalisations
and 40 emergency visits per 100 patients per annum are
attributable to COPD, which could no doubt be reduced by
better compliance to GOLD treatment guidelines.
The BREATHE study also revealed the high social and
functional burden of COPD symptoms. A total of 27% of
COPD patients in the region were kept out of work
by their respiratory problems and 48% of those still in
employment reported an impact on their work. One half of
affected respondents reported comorbidities, and a similar
proportion reported limitations in their activities of daily
living due to COPD. It was also clear that many patients
are poorly informed about COPD, with 30% of patients being
unsure of the underlying cause of their disease and 50%
not acknowledging smoking as a potential cause, or its
management, with 31% never having discussed giving up
smoking with their physician and 42% believing that there
are no effective treatments for their disease. On the other
hand, the vast majority of respondents recognised the need
for better education, and this represents an opportunity for
physicians, health authorities or third parties to construct
programmes for building awareness and knowledge about
COPD in the region.
The BREATHE study also investigated the COPD Assessment
Test (CAT) as a tool for investigating the health status
of individuals with COPD. The good performance of
this patient-reported outcome measure in this general
population sample suggests that it could be a cheap,
easy-to-use and relevant tool for case ﬁnding and disease
monitoring in countries where access to more sophisticated
testing such as spirometry may be limited. In addition,
a patient-reported outcome measure such as the CAT has
an important role to play in establishing and perfecting
patient physician communication. Since knowledge about
COPD in the Middle East and North Africa in individuals
with COPD symptoms appeared to be limited, and attitudes
and beliefs to the disease and its treatment not always
appropriate, more widespread use of the CAT could have an
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important impact on improving patient physician dialogue
and establishing a productive therapeutic alliance.
In summary, the BREATHE study provides valuable input
for improving respiratory care in participating countries. In
Europe and the United States, such initiatives have proved
important in improving awareness of COPD, which in turn has
informed public health planning through governments and
health service planners. It is important to achieve similar
goals in other regions of the world, and the data from
BREATHE will no doubt contribute to this.
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